

MOST INNOVATIVE IN ANAESTHETIC RESEARCH SOLUTIONS

Sintetica SA



Augusto Mitidieri

Corporate CEO
 www.sintetica.com
 +41 091 640 42 50
 amitidieri@sintetica.com



The Medical LiveWire judging panel found that Sintetica is a company whose approach puts them not just at the forefront of medicinal development, but also corporate practice.

Established in 1921, Sintetica SA has championed a values-oriented approach to medical research (particularly in the field of anaesthetics) for almost a century. Fostering a culture of innovation and cooperation, the company are at the forefront of innovative science and excellence in development, production and marketing, operating on a global scale. Based out of Mendrisio, Switzerland – with international offices in Germany, Italy, Austria and the United Kingdom – the pharmaceutical company currently deliver injectable anaesthetics and analgesics to patients worldwide. The Swiss manufacturing sites of Mendrisio and Couvet have a production capacity of 25 million ampoules, five million infusion bags and over five million vials.

Local anaesthesia and pain relief are Sintetica’s primary focuses, the company fully committed to the development of innovative therapies and drugs in local anaesthesia, pain management and neuromodulation. Key to this development is the company’s philosophy of acting with passion and competence, but also utmost respect for the patients they treat. This has allowed the company to operate a more personal service than can be found elsewhere in medical research and development, which can in turn yield better results for the products they represent. All of Sintetica’s efforts and resources are focused towards becoming the leader in these fields by developing novel medicines, as well as better treatment options for physicians and patients worldwide.

Exerting steady influence and progress into global territories, Sintetica can specially cater their services to the markets in which they directly operate, promoting innovation in these markets whilst also bolstering direct business growth. The company’s global capabilities are largely explored in a targeted and measured manner. By specially and strategically selecting international partners the company are able to create affiliate associations with target countries. Utilising their dynamic portfolio of selected branded medicines, the company

